← All trials
NCT04625738
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 6, 2020
- Primary completion
- May 16, 2022
- Completion date
- Aug 6, 2022
- First posted
- Nov 12, 2020
- Last posted
- Nov 12, 2020
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LorraineLead sponsor
- University of LorraineOverall official - principal investigator
- University of LorraineReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.